Synergistic combination therapy for treating ALS
AssigneeBioJiva LLC
InventorsPeter Milner, Nadia Litterman, Mark Midei
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for inhibiting the progression of amyotrophic lateral sclerosis (ALS) in humans. The methods use a synergistic combination of 3-methyl-1-phenyl-2-pyrazoline-5-one and deuterated arachidonic acid or a prodrug thereof, such as 11,11-D2-linoleic acid or an ester thereof.
Claims18
A method for reducing the rate of disease progression of ALS in a patient the method comprising administering to the patient a therapeutically effective amount of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of a deuterated arachidonic acid or a prodrug thereof;
- wherein the rate of disease progression in the patient is less than the aggregate achieved by either drug;
- and wherein the deuterated arachidonic acid or a prodrug thereof is administered using a dosing regimen that includes a loading dose and a maintenance dose.
A method for reducing the rate of loss of functionality in an ALS patient being treated with a therapeutically effective amount of a deuterated arachidonic acid or a prodrug thereof the method comprising further administering a therapeutically effective amount of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof;
- wherein the rate of loss of functionality in the patient is less than the aggregate achieved by either drug;
- and wherein the deuterated arachidonic acid or a prodrug thereof is administered using a dosing regimen that includes a loading dose and a maintenance dose.
A method for reducing the rate of loss of functionality in an ALS patient being treated with a therapeutically effective amount of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof the method comprising further administering a therapeutically effective amount of a deuterated arachidonic acid or a prodrug thereof;
- wherein the rate of loss of functionality in the patient is less than the aggregate achieved by either drug;
- and wherein the deuterated arachidonic acid or a prodrug thereof is administered using a dosing regimen that includes a loading dose and a maintenance dose.
Dependencies are inferred from the claim text.